ExPLoRNA Therapeutics, a Polish biotech company developing mRNA vaccines and therapeutics, has received funding from the Bill & Melinda Gates Foundation (that also backed Bactolife, Cropin and more). The total funding received is more than $800K and will be used for a 14-month project.
The Polish biotech company is the first to receive funding from the Bill & Melinda Gates Foundation and seeks to make mRNA technology more accessible in low-income countries to help fight disease.
How does it increase protein production?
ExPLoRNA specialises in novel cap analogues, the starting part of mRNA that is crucial for enabling the successful production of the encoded protein. ExPLoRNA’s technology increases protein production beyond the scale observable so far with other standard cap analogs.
The project aims to better understand the benefits of ExPLoRNA’s cap analogs, especially in reducing the mRNA dose needed for therapeutic effects in vaccination and monoclonal antibody production settings. The planned experiments include the use of state-of-the-art, clinically validated lipid nanoparticle (LNP) formulations from Acuitas Therapeutics. Acuitas is known for its successful role in providing the LNP technology for one of the only two regulatory-approved mRNA-based COVID-19 vaccines. ExPLoRNA Therapeutics is the first Polish biotech company to receive funding from Bill & Melinda Gates Foundation.
“We are grateful for the foundation’s support to help us achieve our vision. With the help of this grant, we intend to speed up the development of future mRNA vaccines and therapies.” – comments Jacek Jemielity, CEO of ExPLoRNA Therapeutics, and professor at the University of Warsaw.
With passion, ExPLoRNA Therapeutics is harnessing over 20 years of cap analog research and developing ground-breaking innovations of mRNA as a therapeutic platform applies those solutions in unique therapeutic programs, and delivers technology, therapeutic platform, and therapies to pharmaceutical Partners.
